The **Apo B : Apo A1 ratio test** evaluates the balance between atherogenic (harmful) and anti-atherogenic (protective) proteins in the blood to assess cardiovascular disease risk.
**Apolipoprotein B (Apo B)** is present in destructive particles like LDL and VLDL that deposit cholesterol into artery walls, while **Apolipoprotein A1 (Apo A1)** is the primary component of HDL, which clears excess cholesterol.
Calculating the ratio of Apo B to Apo A1 provides a clearer indicator of heart disease and stroke risk than standard cholesterol panels alone. A higher ratio signifies an increased risk of plaque buildup and coronary artery disease.

An **Antiphospholipid Antibody (APLA) Profile Test** is a specialized group of blood tests used to diagnose Antiphospholipid Syndrome (APS), an autoimmune condition. In APS, the body mistakenly produces autoantibodies against its own proteins bound to phospholipids. This reaction significantly increases the risk of abnormal blood clotting in veins or arteries, as well as pregnancy complications like recurrent miscarriages.
The APLA panel typically measures three primary markers: lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein I antibodies. Identifying these autoantibodies helps clinicians evaluate a patient's risk of thrombotic events, guiding appropriate preventive care and targeted anticoagulant treatments.

An **Activated Protein C Resistance (APCR)** test is a specialized blood investigation used to evaluate a person’s risk for developing abnormal blood clots. Activated Protein C (APC) is a natural anticoagulant protein in the body that inactivates specific clotting factors to prevent excessive coagulation.
In APCR, the blood’s response to APC is diminished, leading to a higher tendency to form blood clots—a condition known as thrombophilia. Most commonly caused by the Factor V Leiden genetic mutation, this test measures how long it takes for plasma to clot after adding APC. Identifying APCR helps clinicians assess venous thromboembolism risk and tailor preventive therapies effectively.

A lumps and bumps biopsy is a simple medical procedure used to evaluate unusual growths, soft tissue swellings, or skin lesions. When a lump is detected under or on the skin, a tiny sample of tissue or fluid is removed for laboratory examination. Doctors typically perform this using fine-needle aspiration, core needle biopsy, or a minor surgical excision under local anesthesia. The harvested sample is then analyzed by a pathologist to determine whether the tissue is benign, inflammatory, or malignant. This essential diagnostic test provides clarity, helping your healthcare team create a safe, targeted treatment plan tailored to your needs.

An **Any Lumps and Bumps Test** evaluation refers to a clinical diagnostic approach used to investigate unexplained swellings, masses, or cutaneous nodules on the body.
Rather than a single blood test, this assessment typically combines physical examination with imaging modalities like **ultrasound**, **MRI**, or a **fine-needle aspiration (FNA) biopsy** to determine the characteristics of the lump.
The primary utility is differentiating between benign conditions (such as lipomas, sebaceous cysts, or swollen lymph nodes) and malignant tumors. Identifying the exact nature of the tissue growth ensures accurate staging, patient reassurance, and the timely implementation of appropriate medical or surgical intervention strategies.

An **Antiphospholipid Syndrome (APS) Panel** is a comprehensive blood test used to diagnose an autoimmune disorder characterized by inappropriate blood clot formation and pregnancy complications.
The panel evaluates three primary autoantibodies: **Lupus Anticoagulant (LA)**, **Anti-Cardiolipin (aCL) IgG/IgM**, and **Anti-Beta-2 Glycoprotein I (aβ2GPI) IgG/IgM**. These antibodies mistakenly target normal proteins bound to phospholipids in cell membranes.
A positive panel helps clinicians confirm an APS diagnosis, assessing the risk for deep vein thrombosis (DVT), arterial strokes, or recurrent miscarriages. To fulfill formal diagnostic criteria, positive results must be confirmed by retesting at least 12 weeks later.

An **Antimony Test** is a diagnostic toxicology evaluation used to measure the levels of antimony, a toxic heavy metal, in a patient's blood, urine, or hair.
The test is primarily ordered to investigate acute or chronic heavy metal poisoning resulting from occupational exposure (such as in smelting, glass production, or battery manufacturing) or accidental ingestion.
Elevated antimony levels can indicate systemic toxicity, which can severely impact the respiratory system, cardiovascular health, and gastrointestinal tract. Monitoring these levels is essential for diagnosing environmental toxicity, ensuring industrial workplace safety, and managing effective chelation therapy.

An **Anti-Streptolysin O (ASO) Test** is a diagnostic blood test used to detect a recent or past infection caused by **Group A Streptococcus** bacteria, such as strep throat or scarlet fever.
The test measures the level of ASO antibodies, which the body produces to neutralize streptolysin O, a toxic enzyme released by the bacteria.
Elevated or rising ASO levels are crucial for diagnosing post-streptococcal complications that arise weeks later, most notably **rheumatic fever** and **post-streptococcal glomerulonephritis** (kidney inflammation). It helps clinicians confirm a bacterial trigger when active symptoms of the initial infection have subsided.

An **Anti-Smooth Muscle Antibody (ASMA)** test is a blood test primarily used to help diagnose **Autoimmune Hepatitis (AIH)**, a chronic condition where the body’s immune system attacks its own liver cells.
The test detects autoantibodies that target actin and other components of the cellular cytoskeleton within smooth muscle tissue.
High levels or titers of ASMA are strongly associated with Type 1 Autoimmune Hepatitis. When combined with other diagnostic findings, like elevated liver enzymes, a positive ASMA result is crucial for differentiating autoimmune liver diseases from other causes of liver injury, such as viral hepatitis or fatty liver disease.

An **Anti-Smith (Anti-Sm) Antibodies by EIA** test is a highly specific blood test used to diagnose **Systemic Lupus Erythematosus (SLE)**.
The test detects autoantibodies directed against Smith proteins, which are core components of small nuclear ribonucleoproteins involved in cellular RNA processing.
While Anti-Sm antibodies are only found in roughly 20% to 30% of lupus patients, they are rarely present in other conditions or healthy individuals. Consequently, a positive Enzyme Immunoassay (EIA) result is heavily weighted as a definitive marker for confirming an SLE diagnosis and monitoring potential lupus-related kidney disease complications.

An **Anti-Saccharomyces cerevisiae Antibodies (ASCA IgG)** test is a blood test used to help diagnose inflammatory bowel disease (IBD) and distinguish between its two main types: **Crohn’s disease** and **Ulcerative Colitis**.
The test detects IgG antibodies that target *Saccharomyces cerevisiae*, a common type of dietary yeast.
Elevated levels of ASCA IgG are strongly associated with Crohn’s disease, particularly cases involving the small intestine. When combined with other autoantibody markers, a positive ASCA IgG result provides crucial diagnostic clarity, helping clinicians assess the severity of disease progression and tailor effective treatment strategies.

An **Anti-Ro/SSA IgG Antibodies by EIA (Enzyme Immunoassay)** test checks your blood for specific autoantibodies that mistakenly attack the body's own proteins.
This test is primarily used to help diagnose autoimmune conditions, most notably **Sjögren’s syndrome** (causing severe dry eyes and mouth) and **Systemic Lupus Erythematosus (SLE)**.
A positive result means these antibodies are present, signaling an active autoimmune response. For pregnant individuals, identifying Ro/SSA antibodies is especially crucial, as they can cross the placenta and require careful monitoring to manage the risk of neonatal lupus or congenital heart block in the baby.